Increased serum B-cell maturation antigen levels evaluated with an Elecsys-based serum B-cell maturation antigen assay have a negative prognostic value in patients with newly diagnosed multiple myeloma

EJHaem Pub Date : 2024-12-09 DOI:10.1002/jha2.889
Evangelos Terpos, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Despina Fotiou, Magdalini Migkou, Evangelos Eleutherakis-Papaiakovou, Foteini Theodorakakou, Maria Roussou, Maria Gavriatopoulou, Meletios A Dimopoulos, Efstathios Kastritis
{"title":"Increased serum B-cell maturation antigen levels evaluated with an Elecsys-based serum B-cell maturation antigen assay have a negative prognostic value in patients with newly diagnosed multiple myeloma","authors":"Evangelos Terpos,&nbsp;Ioannis Ntanasis-Stathopoulos,&nbsp;Panagiotis Malandrakis,&nbsp;Despina Fotiou,&nbsp;Magdalini Migkou,&nbsp;Evangelos Eleutherakis-Papaiakovou,&nbsp;Foteini Theodorakakou,&nbsp;Maria Roussou,&nbsp;Maria Gavriatopoulou,&nbsp;Meletios A Dimopoulos,&nbsp;Efstathios Kastritis","doi":"10.1002/jha2.889","DOIUrl":null,"url":null,"abstract":"<p>Background: Serum B-cell maturation antigen (sBCMA) levels have emerged as a potential biomarker for disease monitoring in multiple myeloma (MM) with prognostic value.</p><p>Methods: Herein, we evaluated the sBCMA levels in 166 patients with newly diagnosed MM with an Elecsys-based sBCMA assay.</p><p>Results: Increased sBCMA levels at diagnosis were correlated with inferior survival outcomes in terms of both progression-free and overall survival. In a subset of patients with available samples at the time of disease progression, there was a trend for decreasing sBCMA values.</p><p>Conclusion: Sequential evaluation of sBCMA in prospective studies will determine the value of incorporating sBCMA measurement in clinical practice.</p>","PeriodicalId":72883,"journal":{"name":"EJHaem","volume":"6 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11756978/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EJHaem","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jha2.889","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Serum B-cell maturation antigen (sBCMA) levels have emerged as a potential biomarker for disease monitoring in multiple myeloma (MM) with prognostic value.

Methods: Herein, we evaluated the sBCMA levels in 166 patients with newly diagnosed MM with an Elecsys-based sBCMA assay.

Results: Increased sBCMA levels at diagnosis were correlated with inferior survival outcomes in terms of both progression-free and overall survival. In a subset of patients with available samples at the time of disease progression, there was a trend for decreasing sBCMA values.

Conclusion: Sequential evaluation of sBCMA in prospective studies will determine the value of incorporating sBCMA measurement in clinical practice.

Abstract Image

以electrosys为基础的血清b细胞成熟抗原测定法评估血清b细胞成熟抗原水平升高对新诊断的多发性骨髓瘤患者的预后有负面影响。
背景:血清b细胞成熟抗原(sBCMA)水平已成为多发性骨髓瘤(MM)疾病监测的潜在生物标志物,具有预后价值。方法:在这里,我们用基于elecsys的sBCMA检测方法评估了166例新诊断的MM患者的sBCMA水平。结果:诊断时sBCMA水平升高与无进展和总生存期较差的生存结果相关。在疾病进展时可获得样本的患者子集中,sBCMA值有下降趋势。结论:前瞻性研究中sBCMA的顺序评估将决定将sBCMA测量纳入临床实践的价值。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信